

EMERGING MARKETS: Covid-19 Vaccination Strategies and Challenges

Our Covid-19 vaccination table includes updated information on the immunization strategies selected EMs are pursuing and the challenges they face.

Below are some of this week's key developments. Please do not hesitate to contact us if you want to discuss any of the countries mentioned in more detail.

Click on 'View PDF' to see the table.

HIGHLIGHTS

Vaccine roll-out

- In **Brazil**, the Health Ministry announced a 31% reduction on vaccines to be delivered in May from 46.9mn doses to 32.4mn. The reduction is allegedly caused by delays on the licensing of Covaxin and Sputnik V by the health regulator.
- In **Chile**, health authorities are prioritizing the provision of second doses because of concerns that a single jab of Sinovac's vaccine offers only limited protection; a third of the population has now received a double dose.
- **Hungary** is testing its mass inoculation campaign by temporarily opening up vaccination to all adults willing to get a Sinopharm jab.
- In **Kenya**, which has brought forward phase 2 of its vaccine rollout in response to a third Covid-19 wave, officials face allegations of bribery and cutting lines ahead of priority groups.
- Vaccine supply difficulties have obliged the caretaker government in **Peru** to revise down its vaccination target; it now plans to vaccinate 4.65mn people (14.3% of the population) by 28 July, down from 9mn previously.
- In **Poland**, adults of all age groups will be allowed to register for a Covid-19 jab by 9 May. In addition, the government is
 planning to start mass vaccination in workplaces by mid-May.
- To speed up vaccination in **Russia**, Moscow's authorities are expanding the number of vaccination sites in the city and introducing financial incentives for elderly persons to get immunized.
- South Africa's very slow vaccine rollout should soon accelerate, as a temporary suspension of the J&J vaccine is lifted and arrivals of contracted vaccine doses (31mn from J&J and 30mn from Pfizer) are to ramp up starting this week.

Vaccine procurement

• A deal has been brokered between **Argentina** and Russia's RDIF sovereign wealth fund for a local pharma company (Richmond) to produce the Sputnik V vaccine locally, though the aim of producing at scale as soon as June looks optimistic.

- Indonesia is trying to broaden its vaccine pipeline from China and the US due to delays in the arrival of AZ vaccines from India. Specifically, it is hoping to obtain 90mn to 100mn more doses from China, with 10mn-15mn for this second quarter. Indonesia's vaccination rate has dropped to around 300,000 per day due from a peak of 500,000 due to supply issues.
- **Mexico** has announced that the state-owned Birmex pharma company has reached an agreement with Russia's RDIF to fill and label Sputnik V vaccine vials and package them locally from June.
- The **Philippines** is scheduled to receive a nominal shipment of 15,000 doses of Sputnik V after a call between President Rodrigo Duterte and President Vladimir Putin. Another 485,000 doses are expected in May.
- **Thailand** may accelerate its vaccine purchases to head off criticism that it is too dependent on the local production of AZ, especially with the country going through its most serious spike since the start of the pandemic last year.

Vaccine hesitancy

- In **Colombia**, 28.4% of adults say they will not get vaccinated, down from almost 40% last November, according to the latest Invamer poll.
- A United Surveys poll conducted in April showed that around 69% of **Poland**'s residents were willing to get vaccinated, similar to a March poll.

Infections and new variants

• India will receive medical aid from several countries to combat the worst Covid-19 outbreak in the world. Amid concerns about the spread of the B.1.617 Indian variant, many countries have introduced or are considering border closures with India.

Vaccine diplomacy

- China's government offered help to India with vaccine supplies, despite rising Sino-Indian tensions since a border dispute in June. Overall, Sinopharm has sent 50mn vaccine doses abroad, while Sinovac has sent 156mn doses abroad, including both donations and commercial exports.
- China's embassy in the US will grant visas to inbound US travelers who have received Western-made vaccines, a step back from vaccine nationalism.
- Russia's regulators are set to approve the export-oriented one-jab Sputnik Light vaccine in the first half of May.

Client Portal >>

Macro Research +44 20 7186 8894 Macro@teneo.com

^{© 2021} Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.

Emerging Markets Covid-19 Vaccination Strategies and Challenges

Rating of countries' vaccine roll-out (as of 28 April 2021):



Between 0% and 1% of the total population have received at least one Covid-19 vaccine dose Between 1% and 10% of the total population have received at least one Covid-19 vaccine dose More than 10% of the total population have received at least one Covid-19 vaccine dose

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Israel	Virtually all high-risk adults have been vaccinated.	Israel has the highest vaccination rate in the world, with more than 120 doses per hundred people. 58% of the population has been fully vaccinated. However, only 3% of Palestinians in the West Bank and Gaza have been vaccinated.	Pfizer-BioNTech – Israel is administering the Pfizer vaccine, in exchange for giving Pfizer extensive patient data. Moderna – Israel plans to vaccinate about 100,000 Palestinian workers with the Moderna vaccine. The Palestinian Authority has received more than 310,000 doses: 100,000 Sinopharm, 97,000 AZ, 70,000 Sputnik, 37,000 Pfizer-BioNTech and 2,000 Moderna.
UAE	Emirati citizens, their domestic workers, elderly, sick, and those in health and education are eligible for vaccination without appointment. Other residents eligible for vaccination free of charge.	As of 25 Apr, about 10.3mn shots have been administered (104% of population). The UAE has not reported how many are fully vaccinated since February. Third shots of Sinopharm drug are being given for those with low levels of antibodies. Dubai has emphasized the Pfizer vaccine, Abu Dhabi the Sinopharm vaccine.	Sinopharm and Pfizer-BioNTech are the two approved vaccines. UAE signed agreement to produce Sinopharm domestically.
Chile	Target to vaccinate 5mn people (ca. 26% of population) by end-Q1/2021 has been met. Next target is to vaccinate 15mn people (80% of population) by end H1/2021, which is on track. Medical workers first to receive vaccinations, followed by elderly in care homes; over 65s; key workers in public bureaucracy; people with other co-morbidities.	Pfizer vaccinations started in late Dec but mass campaign using China's Sinovac vaccine started 3 Feb. As of 26 Apr, 7.95mn people (42% of population) have received one dose and 6.2mn (32.6% of population) have received a double dose.	Pfizer-BioNTech – agreement for 10mn doses; Sinovac – agreement for 60mn doses over three years; AZ – agreement for 14.4mn doses. COVAX – agreement for 8mn doses; first delivery of 160,000 AZ doses arrived late- April. CanSino – agreement for 1.8mn doses, with first delivery expected in May. Local regulatory approval for J&J and Sputnik V vaccines pending.
Hungary	Most medical staff and care home residents/staff have been vaccinated. The elderly aged 60+ years, uniformed services, civil servants and people aged 18-59 years with chronic illnesses are the main target groups now. Authorities are launching a ten-day mass vaccination campaign with the Sinopharm vaccine.	Vaccination started on 26 Dec. As of 27 Apr, 3.7mn people (37.8% of population) have received at least one jab and 1.7mn (17.5%) got both shots. The pace of vaccination remains one of the fastest in Europe.	Procurement contracts and deliveries as of 27 Apr via the EU's joint mechanism: AZ – 6.5mn doses (786,600 delivered) Moderna – 1.7mn doses (216,000 delivered). Pfizer-BioNTech – 10.9mn doses (2.56mn delivered). J&J – 4.4mn doses (28,800 delivered). CureVac – 500,000 doses. National-level procurement: Sputnik V – 2mn doses (1.8mn delivered). Sinopharm – 5mn doses (1.7mn delivered).
Poland	The vaccination roll-out is being carried out in four stages (0-3). As of late Apr, vaccination focuses on elderly; people with chronic illnesses; teachers; uniformed services (stage 1). Adults of all age groups will be allowed to register for a Covid-19 jab by 9 May. Vaccination of employees in large and medium- sized companies expected to start in May.	Vaccinations started on 27 Dec. As of 27 Apr, 7.9mn residents (27.4% of population) have received a first jab and 2.6mn (6.8%) had both shots. Government aims to administer 14mn doses during Q2 (in total 20mn doses in H1). The pace of vaccination has been increasing in April.	Procurement exclusively via the EU. Overall, around 100mn doses contracted. As of 27 Apr, 12.9mn vaccine doses delivered. Expected delivery of at least 15mn shots within Q2.

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Singapore	Currently, seniors, healthcare and frontline workers nominated by their employers are eligible for vaccination. The vaccination of those 45 years old will be next. Other groups will be notified by mail as to when their vaccinations start.	As of 18 Apr, 2.21mn doses have been administered (30% of population), of which 1.36mn (22.8%) have received one dose and 849,764 (15%) have received both shots. Moderna vaccinations began in March	The government has concluded agreements with three suppliers, with undisclosed quantities: Pfizer-BioNTech , Moderna and Arcturus .
Greece	Currently vaccinating people aged over 50, those in the second of two high-risk groups and citizens aged 30-39. The latter group is only being offered AZ vaccines. The AZ vaccine is not being offered to Greeks below 30. Pregnant women have been advised to avoid the AZ and J&J vaccines. J&J vaccinations are due to begin on 5 May. The government's target is to deliver 3mn vaccines in total by the end of April. It hopes to have vaccinated half the population by end-June.	As of 26 Apr, Greece had administered 2.8mn vaccines. Of those vaccinated so far, 2mn (18.9% of population) have received at least one jab, while 851,109 (7.9% of population) have received both doses. There has so far been a relatively low uptake in older age groups – 61.1% for over-80s and 58% for 70-79.	Greece is using the Pfizer-BioNTech , AZ and Moderna jabs and is bound to the EU's procurement process. In May, Greece expects to receive 2.1mn doses of the Pfizer-BioNTech vaccine, 450,000 of AZ , 345,000 of Moderna , and 300,000 of J&J . For June, Greece is expecting 2.4mn from Pfizer-BioNTech , 308,000 from Moderna , 960,000 J&J and roughly another 450,000 from AZ .
Czech Republic	Priority is given to frontline medical staff, followed by care home residents and employees; elderly; teachers; persons with chronic illnesses; critical infrastructure workers. As of 23 April, people aged 60-65 years old can register for vaccination.	Vaccinations started on 27 Dec. As of 27 Apr, 2mn residents (21.2% of population) have received a first jab and nearly 1mn (9% of population) got both shots. More than 70% of people aged 70+ years old have been vaccinated.	Procurement has been conducted exclusively via the EU. As of 27 Apr, 2.9mn doses of vaccines delivered. Pfizer-BioNTech and Moderna – 2.27mn delivered out of 12mn doses ordered AZ – 354,814 delivered out 3mn doses ordered. J&J – 1,719 delivered out of 2mn doses ordered. CureVac – 1mn doses ordered. As of 27 Apr, 77.4% of immunizations carried out with Pfizer-BioNTech vaccine; 12.1% with AZ; 10.5% with Moderna.
Turkey	Vaccination program divided into four stages, starting with medical personnel, pharmacy workers and the over 65s, followed by members of the security forces, teachers, those working in the food industry and transportation, and then Stage 2, the 50-64 age group. On 19 Apr, Turkey began vaccinating Group B2 of Stage 2, comprising people in the 55-59 age group. Next will be Group B3 of Stage 2, those in the 50-54 age group.	Vaccine rollout started on 13 Jan. On 2 Apr, vaccinations also began with the Pfizer-BioNTech vaccine. As of 27 Apr, 21.89mn doses have been administered, with 13.44mn (16.1% of population) people receiving a first dose and 8.45mn (10.1%) receiving two doses. Nearly all of the vaccinations have been with Sinovac's CoronaVac.	 Sinovac – approved by regulator and roll- out started; agreement for 50mn doses, of which 16.5 mn individual doses and the equivalent of 10 mn doses delivered in bulk had arrived by 27 Apr. Pfizer-BioNTech – 4.5mn doses, all of which were reportedly delivered by 27 Apr, with another 25.5mn doses planned for delivery before end-Jun. Turkey has not joined COVAX.
Saudi Arabia	All Saudis over 16 are now eligible. Foreign workers in Saudis' homes, food services, and personal grooming will require vaccinations by mid-May to retain work permission.	Vaccinations reportedly started in Dec. As of 26 Apr, 8.4 mn doses have been administered, or 24.06 per 100 people.	Pfizer-BioNTech and AZ approved for administration. Sputnik V – government has secured an unknown number of doses.

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Brazil	Phase 1: health workers; indigenous communities in demarcated territories; over 60s in care institutions; over 75s. Phase 2: 60-74s seniors. Phase 3: persons with comorbidities. Phase 4: education workers, homeless population, security and rescue forces, others.	Vaccinations started in January. As of 27 Apr, 13.96% (29.5mn) of population has received the first dose of Covid vaccine. Meanwhile, 6.22% (13.1mn) was vaccinated with both doses.	 AZ – 21mn doses expected to be delivered to the federal government in May, 108.4mn by June, 210.4mn by year- end. CoronaVac – 5.6mn doses expected to be distributed in May by São Paulo state health institute Butantan. 130 mn doses by year-end. Pfizer – 2.5mn doses expected to be delivered in May. 100 mn by year-end. J&J – 38mn doses expected to be delivered in Q4. Sputnik V – On 26 April, ANVISA (health regulator) rejected governors' request to import the immunizer. Meanwhile, emergency use request still pending regulator's approval. India's Covaxin – purchase of 20mn doses but ANVISA approval yet to come. COVAX – minimum 10% of population quota (42mn) doses. WHO to provide 10- 14mn doses that will be distributed from mid-Feb to June. 2mn AZ and 842,000 Pfizer doses to be received in May. ButanVac – 40mn doses are expected to be delivered from July and 100mn by year-end.
Argentina	Health sector personnel first in line for vaccine, followed in descending order by over 70s; over 60s; security personnel; vulnerable and at-risk in 18-59 age range; education sector; and strategic or vulnerable groups. Government has reiterated promise to provide at least one vaccine dose to over 60s and other at- risk sectors by end-April; the recent regulatory approval of the Sinopharm vaccine for use in the over 60s should help but target depends on avoidance of supply bottlenecks.	Sputnik V vaccinations started on 29 Dec. As of 27 Apr, 7.4mn first doses have been administered (representing 14.5% of population) while 879,000 people (2% of population) have received two doses.	Sputnik V – approved by regulator and roll-out started; agreement for 30mn doses; local production currently undergoing testing. AZ– contract for 23.6mn doses, though most of this to be produced locally. Sinopharm – agreement for 4mn doses, of which around 3mn have now been delivered. COVAX – approx. 1mn doses have been delivered; the government has been criticized for ordering only 20% of its Covax entitlement.
China	Authorities are assessing ways to raise the efficacy of Chinese vaccines, including through higher doses, a third shot, or mixing vaccines. Chinese companies are also testing new mRNA vaccines. The National Health Commission ordered local governments to halt compulsory vaccinations and other heavy-handed measures to encourage vaccination.	As of 27 Apr, 229mn vaccines doses administered, including second doses (15.94% of population), at average daily pace of 4.9mn doses over previous week. Goal to vaccinate 560mn people, or 40% of the population, by end-June will require an even faster daily pace.	Government has approved five domestic vaccines; Sinopharm Beijing , Sinopharm Wuhan, CanSino Biologics,Sinovac Biotech , and Anhui Zhifei Longcom Biopharmaceuticals . Sinopharm says it can produce 100mn doses per month beginning in April, and China aims to produce 3bn doses total in 2021.
India	From 1 May, everyone above 18 is eligible for vaccination. All import curbs on foreign vaccines have been lifted and import duties have been waived. However, the target to vaccinate all above 45 without comorbidities is yet to be realized.	Vaccine roll-out began 16 Jan. As of 26 Apr, around 140mn people have been vaccinated – 10.33% of the population. The positivity rate has increased from 5.3% to 20.3% in four weeks. India has halted AZ vaccine exports to cater to domestic demand. The export of drug Remdesivir and diversion of oxygen to any use other than medical has been banned.	All vaccines are now free to be used in India, whether Indian or foreign, as long as they have been certified as safe in the country of origin. Import duties have been waived. However, Pfizer wants an assurance of indemnity before it supplies doses to India. This is under negotiation.

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Mexico	Frontline medical workers first in line followed by the over 60s age cohort; plan to vaccinate all this sector by end-April pushed back to end-May. Original plan to vaccinate up to 35% of population by June could now be reset given slow start to vaccination campaign and supply difficulties.	Vaccinations started 24 Dec. Rollout stalled mid-Jan to mid-Feb but subsequently resumed with new vaccines from wider array of suppliers. As of 27 Apr, 12.1mn people (9.4% of population) have received one dose of the vaccine, with 5.9mn people (4.68% of population) fully inoculated.	AZ – agreement for 77.4mn doses. US has supplied Mexico with 2.7mn doses from its AZ supply. Pfizer – 34mn doses ordered, of which 8.7mn delivered as of 26 Apr. CanSino – 35mn doses agreed; deliveries reached 2.7mn as of 26 Apr. Sputnik V – agreement for 24mn doses, though only 1.1mn doses have arrived as of 26 Apr. COVAX – 51.5mn doses agreed; Sinovac – agreement for 20mn doses, with 5mn delivered as of 26 Apr; Sinopharm – agreement for 12mn doses though local regulatory clearance pending.
Russia	Vaccination available to all citizens. Immunization target: 68.6mn people. The initial target to vaccinate 20mn residents in Q1 has not been realized. In Moscow, authorities are offering financial incentives for elderly to get vaccinated.	Vaccinations started in early Dec. As of 27 Apr, an estimated 12.2mn residents (8.3% of population) received at least one jab and 7.7mn (5.2% of population) were fully vaccinated.	Russia relies solely on its own Sputnik V vaccine. Two more domestic vaccines - EpiVac and CoviVac have been approved by the country's regulators, but their production volumes are low. The export-oriented one-jab Sputnik Light vaccine is expected to be approved in the first half of May.
Colombia	Plan is to vaccinate 70% of the population (35mn people) by end-2021. Medical personnel first in line, followed by elderly and clinically vulnerable. Target is to vaccinate 26mn by end-July. Roll-out based on network of 3,000 vaccination centers.	Vaccination campaign started on 17 Feb with Pfizer vaccine. As of 25 Apr, 4.45mn doses administered (8.8% of population), with 1.4mn people (2.8% of population) having received two doses. Government under pressure over slow start to vaccination campaign, though daily vaccinations have accelerated since Mar.	Pfizer-BioNTech – agreement for 10mn doses. AZ – 10mn doses agreed. J&J – agreement for 9mn doses; local regulatory clearance granted. Sinovac – agreement for 7.5mn doses. Moderna – agreement for 10mn doses but arrival not expected until mid-2021. COVAX – first delivery of 117,000 doses arrived 1 Mar, 2mn doses expected by May.
South Korea	First doses will be distributed to medical workers and elderly. Government has signed preapproval agreements for enough doses to vaccinate entire population.	Vaccinations of frontline workers and vulnerable populations began on 26 Feb, with AZ vaccine distributed to medical workers and under-65 residents of long-term care facilities. As of 28 Apr, 5% of the population have received one dose of the vaccine while 0.3% are fully vaccinated. Distribution of Pfizer doses received from COVAX to medical workers began on 27 Feb. The government is expecting to receive doses for roughly 1mn people from Pfizer by the end of March, which will be distributed to people over 75 beginning in April.	Government was slow to conclude purchasing agreements, believing it could wait due to low case numbers. AZ : 20mn doses; Pfizer-BioNTech: 20mn doses; Moderna : 40mn doses; J&J : 6mn doses; COVAX : 20mn doses.
Indonesia	Frontline healthcare workers estimated at 1.3mn have been vaccinated first, followed by security personnel, then 17mn teachers; working age 15 – 59 will are also now being vaccinated, ahead of the elderly simultaneously. Vaccines procured by central government and distributed; free, not mandatory. Government is allowing the private sector to purchase vaccines for their employees.	Second phase of vaccination has started, focusing on the elderly and the active workforce. As of 28 Apr, 12.02mn (4.4% of population) have received at least one shot. Delays in AZ deliveries has led to uneven daily vaccination rates.	Sinovac – 125mn doses; Pfizer- BioNTech – 100 mn doses; Novavax – 100mn doses; COVAX initiative – 100mn doses; AZ – 100mn doses; private sector importation unknown

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Peru	Phase 1 focused on medical and other frontline emergency personnel, including election staff. Phase 2 focused on over 60s, those with co- morbidities, and indigenous population. Caretaker government has revised down its original goal and now wants 4.65mn people vaccinated by 28 July when handover to new government is scheduled; government also says it will leave sizeable stock of vaccines for incoming government.	Nov 2020 political crisis interrupted procurement process, but caretaker government accelerated procurement efforts from early 2021. Vaccinations using Sinopharm vaccine started 9 Feb. Pfizer vaccines now also being administered. As of 27 Apr, 885,000 people have received a first dose (representing 2.7% of population). 587,000 people (1.8% of population) have received two doses.	Sinopharm – contract for 38mn doses, 1mn of which have arrived. AZ – agreement for 14.4mn doses to arrive from Sep. Pfizer-BioNTech – agreement for 20mn doses, 25% of which to arrive by June. COVAX – agreement for 13.2mn doses; first batch of 117,000 doses arrived 10 Mar. Ongoing talks with J&J (5mn doses), Russia's Gamaleya Institute (for 10mn Sputnik V doses, 3.1mn of which could potentially arrive over Apr/May), Moderna (12mn doses), Sinovac (7mn doses), and CureVac.
Malaysia	Frontline medical workers, police and army officials are being prioritized in the first stage of the vaccine roll-out. The second phase starting from 19 Apr and to run through August will involve senior citizens, high-risk groups with co- morbidities and the disabled. The third phase starting in May will cover all adults above 18.	As of 27 Apr, 822,201 people (2.5% of the population) have received their first dose of the vaccine, with an additional 513,044 (1.6%) already having received two doses.	Pfizer-BioNTech – 32mn doses secured; Sinovac – 12mn doses; AZ – 6.4mn doses via COVAX facility and another 6.4mn contracted directly; Sputnik V – 6.4mn doses; CanSino Biologics – 3.5mn doses
Thailand	In the first phase, the priority will be the elderly, frontline healthcare and social workers and those with co-morbidities. The second phase will focus on provinces with the highest Covid incidences. Government may allow private sector importation.	As of 25 Apr, 1.15mn (1.64% of population) of first doses have been administered, with another 127,000 (0.2%) having been fully vaccinated.	Sinovac – 2mn, but the country is negotiating for an additional 6mn doses. AZ – 61mn (imported and local joint venture)
Philippines	Vaccine roll-out will prioritize healthcare workers; workers in education, social welfare agencies; law enforcement and military personnel; the poor; senior citizens; other vulnerable populations. Private sector is allowed to import vaccines, although some are required to make counterpart donations. The private sector importation may make up the bulk of Q2 and Q3 vaccinations.	As of 26 Apr, around 1.77mn (1.4% of population) have received a one dose while 0.2% are fully vaccinated. Total Sinovac vaccines received is 2mn. Also, 480,000 AZ vaccines from the COVAX initiative have arrived.	Various vaccines totaling 40mn are expected through July: 13.5mn Sinovac , 1.2mn Moderna , 7.47mn AZ , 14mn Sputnik V ; 3mn Novavax and 1.5mn J&J . Government claims to have ordered a total of 132mn doses through the next 12 months.
Kenya	Kenya expects to inoculate 50% of its 50mn population by June 2022. Priority to be given to frontline medical workers, essential workers (police, teachers, students, immigration officials), workers in hospitality sector, people with comorbidities, and those aged 58+, people in informal settlements.	First 1.02mn AZ/COVAX vaccine doses arrived 2 Mar; rollout began 5 Mar. Vaccine doses have been distributed to regional depots in all 47 counties, but shortages reported in high-uptake areas like Nairobi. As of 21 Apr, 1.4% of population had been vaccinated.	Kenya is heavily reliant on COVAX (total of 24mn doses expected, 3.56mn in Feb- May). India has donated 100,000 AZ shots; additional vaccines in pipeline from the African Union's African Vaccine Acquisition Task Team (AVATT) and possibly other countries or manufacturers.
Egypt	Medical staff and vulnerable populations are eligible.	Egypt has administered an estimated 832,000 vaccines, representing 0.81 per 100 people. Reporting has been incomplete and sporadic. Egypt is charging patients for vaccinations, in contravention of global trends.	COVAX – agreement for 20mn doses of AZ vaccine. Sinopharm – agreement for 40mn doses; 350,000 reportedly received. Pfizer-BioNTech – contracts reportedly signed for 20mn. AZ – agreement for 30mn doses Sputnik V – 25mn have been secured. Egypt has also signed agreements to manufacture Sputnik V and Sinovac vaccines domestically.
Pakistan	Vaccine registration for those above 40 opened on 27 April. Meanwhile, walk-in vaccination is available for those above 50. Those above 65 and frontline workers are still being vaccinated.	As of 13 Apr, 0.59% of the population had received at least one dose of the vaccine. 0.5mn doses of China's Sinopharm arrived on 1 Feb. 50,000 doses of Sputnik V were received by a private logistics firm. As infections rise, on 26 April China shipped 1mn doses as an emergency measure.	Emergency use permission given to AZ , Sinopharm and CanSino . Both Chinese vaccines are currently undergoing clinical trials. Four more vaccines in the pipeline.

T Teneo

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Nigeria	Vaccination targets: 40% of population in 2021, 70% by end-2022. Healthcare personnel; people over 50; people with underlying health conditions to be prioritized. Most heavily affected states will be prioritized in allocation of doses.	First batch (3.9mn doses) of AZ vaccine supplied by COVAX arrived 2 Mar; vaccination campaign has commenced. As of 25 Apr, 1,171,515 people (0.57% of population) had received their first jab.	20% of vaccines supposed to be supplied through the COVAX initiative. Government expects total of 58mn vaccine doses from COVAX (16mn) and the African Vaccine Acquisition Task Team (AVATT, 42mn). Government also expressed interest in procuring Sputnik V and/or Sinovac/Sinopharm vaccines.
South Africa	Plans to vaccinate 40mn people by Feb 2022; phase 2 expedited in response to third wave. Phase 1 (Feb-May): ca. 1.25mn frontline medical workers; Phase 2 (May-Oct): 16.6mn essential workers (mining, hospitality, media, taxi industry), people in institutions, over 60, with comorbidities; Phase 3 (Nov-Feb): 22.6mn remaining adult population.	Limited "implementation study" rollout of J&J vaccine started on 18 Feb after last-minute pivot away from AZ vaccine due to concerns over efficacy against locally dominant B.1.351 variant. Temporarily suspended J&J vaccinations resume on 28 Apr, while Phase 2 is due to start on 17 May. As of 13 Apr, 0.49% of population had been vaccinated.	Procurement lagging but 61mn doses in pipeline – from J&J and Pfizer. Deliveries to ramp up in May but largest volumes due in Q3/4. J&J – 31mn (2.8mn expected in Q2) Pfizer-BioNTech – 30mn (starting Q2) Vaccine uptake from AVATT and COVAX allocations unconfirmed
Taiwan	Priority groups (868,000 people): health care personnel; essential workers; nursing home staff; military; social welfare workers. Outside priority groups, individuals can obtain vaccinations through a self-paid program if they intend to travel abroad (excluding tourism).	45,387 people, or 0.2% of population, have received first dose, including from priority groups vaccinated through 26 April, including 38,222 from priority groups and 7,165 through self-paid program.	20mn doses ordered: AZ – 10mn doses and 5mn additional AZ doses expected through COVAX. Moderna – 5mn doses, but delivery dates are unclear. First batch of 200,000 AZ doses through COVAX arrived in early April.

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.